Medicare AdvantageDocumentationMedium impact
MA08.117e, Isatuximab-irfc (Sarclisa®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.117e establishes medical necessity criteria, billing coding requirements, and updated guidelines for isatuximab-irfc (Sarclisa®), a monoclonal antibody used in multiple myeloma treatment. This recent policy (effective 03/24/2025) requires billing and clinical teams to align coding practices and ensure documentation supports medical necessity for this specialty pharmaceutical.
Action Required
By 03/24/2025: Billing and clinical teams must review the full policy text at the provided URL to identify specific HCPCS/CPT codes for isatuximab-irfc administration and obtain complete medical necessity criteria requirements. Update billing software, prior authorization templates, and clinical documentation requirements accordingly. Verify that all claims for Sarclisa® include proper medical necessity documentation per updated guidelines. Contact the insurance carrier (IBX) directly for complete code list and specific medical necessity parameters if not detailed in policy summary. Failure to comply with updated medical necessity criteria will result in claim denials or recoupments.